Clinical Trials Logo

HCC - Hepatocellular Carcinoma clinical trials

View clinical trials related to HCC - Hepatocellular Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06375317 Not yet recruiting - Clinical trials for HCC - Hepatocellular Carcinoma

HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure

Start date: April 30, 2024
Phase: Phase 2
Study type: Interventional

For patients with advanced liver cancer who have progressed after first-line targeted and immunotherapy , there is currently no standard treatment regimen for second-line therapy. this study aims to explore the efficacy and safety of HAIC combined with PD-L1 and Regorafenib in patients with advanced liver cancer who have failed immunotherapy, not only providing new treatment options for second-line therapy of liver cancer, but also laying the foundation for research on the combination of HAIC and PD-L1 inhibitors plus Regorafenib, which has significant scientific research significance and clinical value.

NCT ID: NCT05665348 Not yet recruiting - Metastatic Cancer Clinical Trials

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

TRIPLET
Start date: February 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

TRIPLET HCC is a phase II-III trial that assess the effectivness of addition of ipilimumab to the combination atezolizumab-bevacizumab, on global survival and response to the treatment, for patients with advanced or metastatic hepatocellular carcinoma. The theoretical duration of the study is 5 years. In the scope of this study, each patient will have 2 years of treatment and 2 years of follow-up from their enrollment date.